As of Oct 20
| +0.14 / +6.67%|
The 2 analysts offering 12-month price forecasts for Proteostasis Therapeutics Inc have a median target of 11.00, with a high estimate of 13.00 and a low estimate of 9.00. The median estimate represents a +391.07% increase from the last price of 2.24.
The current consensus among 3 polled investment analysts is to Buy stock in Proteostasis Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.